At present, ARV‐471, a PROTAC degrader of ER for the treatment of breast cancer, is at the phase III clinical trial, along with few dozens of degraders, having entered or about to enter the early phase of clinical trials. The gene discussed is ESR1; the disease is breast carcinoma.